KSKamran Safa

Kamran Safa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kamran Safa has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Brain-gut-bone axis; a review of the association between gut microbiota and osteoporosis

    by Sina Salem Ahim, Sara Aghaei, Farzin Banei, Mohammad Mousavi, Mohammad Shahsavan, Kamran Safa, Amin Norouzbeygi, Elahe Zaremoghadam, Faezeh Nesaei

    The brain-gut-bone axis plays a crucial and complex role in regulating bone metabolism, particularly in the context of osteoporosis. This multidirectional communication network integrates signals from several physiological systems, including the gut microbiota, immune system, nervous system, and hormonal environment, all of which collectively influence the balance between bone formation by osteoblasts and bone resorption by osteoclasts. The gut microbiota contributes to this axis by producing metabolites such as short-chain fatty acids (SCFAs) and modulating systemic inflammation, which in turn can affect bone cell activity and mineralization processes. The immune system participates through cytokine signaling that either promotes or inhibits bone resorption and formation, linking inflammation to bone health. Meanwhile, the nervous system, via autonomic and sensory pathways, regulates nutrient absorption, bone blood flow, and directly modulates bone cell function through neuropeptides and neurotransmitters. Hormonal factors, including parathyroid hormone, sex steroids, and gut-derived hormones like serotonin, further modulate bone turnover by fine-tuning osteoblast and osteoclast activity. Disruptions in any component of this axis, such as dysbiosis of the gut microbiota, chronic inflammation, neurotransmitter imbalance, or hormonal deficiencies can lead to dysregulated bone remodeling, favoring increased bone resorption, decreased bone formation, and eventually decreased bone density. This manifests clinically as osteoporosis, characterized by fragile bones and elevated fracture risk. Therefore, understanding and targeting the brain-gut-bone axis presents promising therapeutic opportunities. Interventions such as probiotics, anti-inflammatory therapies, neuromodulation, and hormone replacement can potentially restore the balance in this axis, improving bone health and reducing osteoporosis progression. This integrative approach highlights the importance of systemic interactions and opens new avenues for precision medicine in bone metabolic disorders.


  • Open Access

    Economic trend in kidney transplantation costs in the world; insights from the ISN global kidney health atlas 2019-2023

    by Sina Salem Ahim, R.J. Arismani, M. Miri, S.G. Kermani, M.S.Q. Nou, Z. Eydizadeh, A. Emadzadeh, K. Safa, M. Safari

    Introduction: Kidney transplantation is a critical treatment for end-stage kidney disease, but its costs vary widely across countries and over time. Objectives: This study investigates changes in kidney transplantation costs between 2019 and 2023 using data from the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA). Methods: This ecological study analyzed kidney transplantation costs reported globally for 2019 and 2023 using data from the ISN-GKHA. The study included countries with complete cost data for both years, excluding those with missing or inconsistent records. Data collection focused on extracting first-year and subsequent annual transplantation costs from the publicly available ISN database. The primary outcome was the change in transplantation costs over time, evaluated to identify trends and regional variations in expenses across the included countries. Results: The trend from 2019 to 2023 in kidney transplantation costs varies by continent and globally. In Latin America, Brazil showed the highest increase, while Bolivia had the smallest. Oceania and Southeast Asia saw Australia with the largest increase and Indonesia with a decrease. Western Europe had the Netherlands with the greatest rise and Germany with a decrease. Saudi Arabia had the highest increase in the Middle East, while the West Bank and Gaza had the least. South Asia’s Bangladesh showed a modest increase. In North America, the United States experienced the largest increase, whereas Canada had a decrease. North and East Asia saw Japan with the most notable increase and China with a decrease. Africa had Morocco with the highest increase and Egypt with the smallest. Eastern and Central Europe recorded the largest rise in Slovenia and the smallest in Serbia. Overall, the United States had the most significant increase, while Germany showed the greatest decrease. Conclusion: The findings highlight significant regional disparities in kidney transplantation costs globally, emphasizing the necessity for targeted healthcare policies and ongoing monitoring to ensure cost-effective and equitable access to transplantation services worldwide.

  • Open Access

    A systematic review and meta-analysis on the association of triglyceride-glucose index levels with risk of gestational diabetes mellitus

    by Maryam Farajisani, Shirin Shamsghahfarokhi, Zahra Hamidi Madani, Zeinab Zamanpour, Hamid Rastad, Sara Ghaseminejad Kermani, Kamran Safa, Leila Ashrafi, Forouhar Darabi

    Introduction: Gestational diabetes mellitus (GDM) is a common metabolic disorder during pregnancy, and the triglyceride-glucose (TyG) index is among the indicators that can predict the occurrence of gestational diabetes. Accordingly, our goal was to examine the relationship between the TyG index and GDM. Materials and Methods: Databases of Scopus, PubMed, Embase, Web of Science, Cochrane, and Google Scholar search engine were used for articles published until September 5, 2025. Data was analyzed using STATA 14. Tests with P values<0.05 were considered statistically significant. Results: High TyG index in general (OR:1.77, 95% CI: 1.56, 2), in the second one-third (OR:1.90, 95% CI: 1.08, 3.36), third one-third (OR:3.94, 95% CI: 2.07, 7.50), second quartile (OR:1.24, 95% CI: 1.07, 1.44), third quartile (OR:1.58, 95% CI: 1.28, 1.94), fourth quartile (OR:2.42, 95% CI: 1.85, 3.17), second quantile (OR:1.23, 95% CI: 1.05, 1.43), third quantile (OR:1.44, 95% CI: 1.23, 1.68), fourth quantile (OR:2.15, 95% CI: 1.41, 3.28), fifth quantile (OR:2.92, 95% CI: 1.96, 4.37) increased the risk of GDM. Furthermore, high TyG index levels increased the risk of GDM in China (OR:1.84, 95% CI: 1.59, 2.13), Korea (OR:1.43, 95% CI: 1.08, 1.89), cohort studies (OR:1.82, 95% CI: 1.60, 2.07), women groups with mean ages ≥ 35 (OR:2.54, 95% CI: 1.84, 3.51), and women with BMIs ≥ 25 (OR:2.56, 95% CI: 2.06, 3.18). Conclusion: High TyG index levels increased the risk of GDM by about 77%, and higher TyG index levels led to even higher possibilities of GDM occurrence. Additionally, obese and overweight women and those aged ≥ 35 were more exposed to this disease than other women. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251143086) and Research Registry (UIN: reviewregistry2046) websites.

  • Open Access

    Vitamin D deficiency in children with urinary tract infection; a systematic review and meta-analysis

    by Mehrnaz Nazari Rad, Hamid Rastad, Leila Ashrafi, Sara Ghaseminejad Kermani, Kamran Safa, Sina Salem Ahim, Roozbeh Roohinezhad, Rasoul Jafari Arismani, Baharak Maddahi

    Introduction: Urinary tract infection (UTI) is among the most common bacterial infections in children, and evidently, it is associated with vitamin D deficiency. Accordingly, the present study intended to examine the frequency of vitamin D deficiency in children with UTI. Materials and Methods: Databases Scopus, PubMed, Embase, Web of Science, Cochrane, and Google Scholar Search Engine were used for articles published until August 1, 2025. Data was analyzed using STATA 14. Tests with P values <0.05 were considered statistically significant. Results: The frequency of vitamin D deficiency in the total population of children with UTI was, in case-control studies, and in cohort studies were 42%, 44%, and 38%, respectively. Furthermore, the rates of vitamin D deficiency in children with UTI aged under 3 years, those aged 3 to 5 years, and children older than 5 years were 21%, 46%, and 71%, respectively. Additionally, vitamin D insufficiency frequency in the total population of children with UTI, in case-control studies, and cross-sectional studies was 30%, 34%, and 22%, respectively. Moreover, the rates of vitamin D insufficiency in children with UTI aged under 3 years and those aged 3 to 5 years were 30% and 33%, respectively. Vitamin D deficiency was observed in 60% of the girls and 42% of the boys with UTI. Approximately 47% of the Asian and 20% of the European children with UTI suffered from vitamin D deficiency, and the frequency of vitamin D insufficiency in Asian and European children with UTI was 34% and 24%, respectively. Conclusion: Approximately half of the children with UTI suffered from vitamin D deficiency, and one-third of them faced vitamin D insufficiency. The increase in the age of the children added to the percentage of children with vitamin D deficiency or insufficiency. Furthermore, Asian children were at higher risk compared with European children, and females were exposed to higher risks than males. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251122224) and Research Registry (UIN: reviewregistry2033) websites.

  • Open Access

    Administration of vadadustat for anemia of chronic kidney disease; an updated review

    by Sajad Ataei Azimi, Asaad Abass Fadhel Khalif, Ahmadreza Siyasari, Zahra Bazargani, Peyman Khajehnabi, Sara Ghaseminejad Kermani, Kamran Safa, Shirin Shamsghahfarokhi

    Chronic kidney disease (CKD) is a global health burden, often complicated by anemia due to impaired erythropoietin production and iron dysregulation. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has emerged as a promising therapeutic option for managing anemia in CKD patients. By stabilizing hypoxia-inducible factors, vadadustat enhances endogenous erythropoietin production and improves iron metabolism, offering a novel approach to treating CKD-associated anemia. Recent clinical trials demonstrate that vadadustat effectively increases hemoglobin levels, reduces the need for erythropoiesis-stimulating agents (ESAs), and improves patients’ quality of life. However, concerns regarding its safety, including potential risks of thromboembolic events and hypertension, warrant careful patient selection and monitoring. Comparative analyses with standard therapies, such as ESAs and other HIF-PH inhibitors, highlight vadadustat’s advantages in terms of oral administration and cost-effectiveness, while also identifying areas for further research.